1000th D2d Participant in the Nation Enrolled at MHRI!
MHRI, collaborating clinical site for
the Vitamin D and type 2 diabetes (D2d) trial, enrolled the 1000th
randomized participant in the nationwide study.
MedStar has been a recruitment leader and is currently the only site
in the D2d study that has reached 90% of its time-adjusted goal. Out of all
the sites across the United States, the MedStar site has been the first to
reach 60% of it's goal, with a total of 90 participants out of a 150-patient
goal. MedStar currently is conducting the study at the Hyattsville University Town Center MHRI offices and at the Good Health Center at MedStar Good Samaritan Hospital.
The D2d study is a large clinical trial taking place in more than 22
cities across the United States and is funded by the National Institutes of
Health and the American Diabetes Association. The goal of the D2d study is to determine whether Vitamin D supplementation is safe and effective in delaying the onset of type 2 diabetes in people at risk for the disease and to gain a better understanding of how vitamin D affects glucose metabolism. The D2d study will enroll approximately 2,400 participants who are at
risk of developing type 2 diabetes. Participants are randomly assigned to
receive either vitamin D or placebo and be followed for up to 4 years for
development of diabetes. The D2d
study is expected to define the role of vitamin D supplementation in modifying
diabetes risk in people at risk for the disease.
Congrats to the D2d team and keep up the great work!
Comments
Post a Comment